Breaking News

NightHawk Biosciences Building Advanced Biosafety Level 2 Lab

Enhances research capabilities in infectious disease and biodefense.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

NightHawk Biosciences, a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, announced the construction of an advanced biosafety level 2 (BSL-2) laboratory, adding biodefense and infectious disease capabilities to its research facilities in Research Triangle Park, NC.   Jeff Wolf, NightHawk’s CEO, said, “Given the unprecedented global biological threats facing our nation, both natural and man-made, this new, state-of-the-art BSL-2 laboratory ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters